An observational study in Cholangiocarcinoma, Cholangiopathy and Biliary Stricture, sponsored by Germans Trias i Pujol Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-14.
Sponsored by Germans Trias i Pujol Hospital · Observational
Endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP) remain fundamental tools for the diagnosis and treatment of many pancreatobiliary diseases.
However, there are situations in which these procedures face limitations, such as the evaluation of indeterminate ductal strictures or the management of complex choledocholithiasis.
Direct visualization of the biliary and pancreatic ducts has proven to be a useful and effective alternative in such cases. It also has a safety profile comparable to conventional ERCP, with only a slight increase in the incidence of adverse events.
Nevertheless, due to the associated increase in costs, most centers have adopted a stepwise approach in their diagnostic and therapeutic algorithms, using this technique only after multiple ERCPs.
Although the evidence is still limited, recent studies suggest that early use of direct cholangiopancreatoscopy could be a cost-effective strategy due to its increased efficacy.
In this regard, collecting data on direct cholangiopancreatoscopy would be of interest to generate robust conclusions on cost-effectiveness in routine clinical practice.
This study aims to objectively assess the real-world use of direct cholangiopancreatoscopy in our setting, with the goal of confirming technical aspects, efficacy, and safety, and ultimately conducting cost-effectiveness evaluations to determine the optimal point in the algorithm at which this technique should be introduced.
Endoscopic procedures, more specifically endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP), remain fundamental in the study and/or treatment of many pancreatic and biliary tract diseases.
However, there are certain situations in which these procedures face limitations, whether due to the characteristics of the pathology itself or the technique's constraints. This is the case, for example, in the evaluation of indeterminate ductal strictures or the management of complex choledocholithiasis, where the diagnostic or therapeutic yield is often suboptimal.
Direct visualization of the biliary and pancreatic ducts has been shown to be a useful and effective alternative in such scenarios. Its safety profile is similar to that of conventional ERCP, with only a slight increase in the incidence of adverse events.
Despite this, the increased costs associated with this technique have led most centers to adopt a stepwise approach in their clinical algorithms. In general, conventional ERCP is used initially, and direct cholangiopancreatoscopy is only considered after several failed ERCPs.
While the economic evidence remains limited, recent studies suggest that early implementation of this technique could be a cost-effective solution, due to its high efficacy and the potential reduction in the total number of procedures required.
In this context, collecting data on the use of direct cholangiopancreatoscopy would be valuable to generate robust conclusions regarding the real-world efficacy and cost-effectiveness of the technique in routine clinical practice data that is currently lacking.
This study aims to objectively assess the real-world use of direct cholangiopancreatoscopy in our setting, to confirm technical, efficacy, and safety data for both its diagnostic and therapeutic indications, and ultimately to perform cost-effectiveness analyses to help determine the optimal point within the clinical algorithm at which this technique should be introduced.
Patients with biliopancreatic pathology fo whom a cholangiopancreatoscopy is performed in hospitals in Spain.
Exclusion Criteria:
Patients with biliopancreatic pathology who undergo cholangiopancreatoscopy, are over 18 years of age, and have signed the informed consent
Procedure: Cholangiopancreatoscopy
Direct cholangiopancreatoscopy by single operator
Timing of cholangioscopy in the management of complex biliary pathologies.
To determine the optimal timing for the use of direct cholangiopancreatoscopy in the management of complex choledocholithiasis and the evaluation of indeterminate biliary strictures.
Time frame: Through study completion, an average of 1 year.
Diagnostic and therapeutic success rate in cholangioscopy.
To assess whether the effectiveness of the main indications for direct cholangiopancreatoscopy in our setting (complex choledocholithiasis, evaluation of indeterminate strictures) aligns with the currently available evidence. The evaluation will include direct visualization of target lesions, diagnostic accuracy, number and usefulness of the biopsies, diagnosis achieved and stone clearance rate.
Time frame: Through study completion, an average of 1 year
Incidence of procedure-related adverse events following cholangioscopy.
To evaluate the rate of adverse events associated with direct cholangiopancreatoscopy for its main indications in our setting (complex choledocholithiasis, evaluation of indeterminate strictures) and to assess whether these findings align with the currently available evidence. The evaluation will include post-ERCP pancreatitis, cholangitis, bleeding, perforation, mortality.
Time frame: 1 month
Incremental cost-effectiveness ratio of early cholangioscopy compared to repeated ERCPs.
To compare early cholangioscopy versus repeated ERCPs in both diagnostic and therapeutic indications for complex biliary pathologies, in terms of cost-effectiveness. The analysis will consider procedure-related expenses (ERCPs, Cholangioscopy), hospital admissions and length of hospitalization, ICU admission, number of outpatient visits, need for surgery, imaging studies, success rate and time until complete resolution or end of management.
Time frame: Through study completion, an average of 1 year.
No study locations are listed for this record.
Plan to share: Yes — Data obtained through this study may be provided to qualified researchers with academic interest in cholangiopancreatoscopy and biliopancreatic diseases. Data or samples shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party. Data requests can be submitted starting 10 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.
Supporting information: Study protocol, Sap, Icf, Csr, Analytic code
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Germans Trias i Pujol Hospital